| Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer M Annala, G Vandekerkhove, D Khalaf, S Taavitsainen, K Beja, ... Cancer discovery 8 (4), 444-457, 2018 | 454 | 2018 |
| Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2 … DJ Khalaf, M Annala, S Taavitsainen, DL Finch, C Oja, J Vergidis, ... The Lancet Oncology 20 (12), 1730-1739, 2019 | 286 | 2019 |
| The New and Improved Two-Sample t Test HJ Keselman, AR Othman, RR Wilcox, K Fradette Psychological Science 15 (1), 47-51, 2004 | 165 | 2004 |
| Trimming, transforming statistics, and bootstrapping: Circumventing the biasing effects of heterescedasticity and nonnormality HJ Keselman, RR Wilcox, AR Othman, K Fradette Journal of Modern Applied Statistical Methods 1, 288-309, 2002 | 100 | 2002 |
| Health-related quality of life for abiraterone plus prednisone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: results from a phase II … DJ Khalaf, K Sunderland, BJ Eigl, CK Kollmannsberger, N Ivanov, ... European urology 75 (6), 940-947, 2019 | 76 | 2019 |
| Long-term outcomes following hepatic resection and radiofrequency ablation of colorectal liver metastases A McKay, K Fradette, J Lipschitz HPB surgery 2009, 2009 | 76 | 2009 |
| Wait times from presentation to treatment for colorectal cancer: a population-based study H Singh, C De Coster, E Shu, K Fradette, S Latosinksy, M Pitz, M Cheang, ... Canadian Journal of Gastroenterology and Hepatology 24, 33-39, 2010 | 65 | 2010 |
| Adaptive robust estimation and testing HJ Keselman, RR Wilcox, LM Lix, J Algina, K Fradette British Journal of Mathematical and Statistical Psychology 60 (2), 267-293, 2007 | 65 | 2007 |
| Comparing measures of the ‘typical’score across treatment groups AR Othman, HJ Keselman, AR Padmanabhan, RR Wilcox, K Fradette British Journal of Mathematical and Statistical Psychology 57 (2), 215-234, 2004 | 65 | 2004 |
| Canadian breast cancer guidelines: have they made a difference? S Latosinsky, K Fradette, L Lix, K Hildebrand, D Turner CMAJ 176 (6), 771-776, 2007 | 63 | 2007 |
| Conventional And Robust Paired And Independent-Samples t Tests: Type I Error And Power Rates K Fradette, HJ Keselman, L Lix, J Algina, RR Wilcox Journal of Modern Applied Statistical Methods 2 (2), 22, 2003 | 61 | 2003 |
| Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov. 2018; 8: 444–457. doi: 10.1158/2159-8290 M Annala, G Vandekerkhove, D Khalaf, S Taavitsainen, K Beja, ... CD-17-0937.[Abstract][CrossRef][Google Scholar], 0 | 50 | |
| A randomized phase II cross-over study of abiraterone+ prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC). KN Chi, M Annala, K Sunderland, D Khalaf, D Finch, CD Oja, J Vergidis, ... Journal of Clinical Oncology 35 (15_suppl), 5002-5002, 2017 | 49 | 2017 |
| Cancer incidence, mortality, and stage at diagnosis in First Nations living in Manitoba KM Decker, EV Kliewer, AA Demers, K Fradette, N Biswanger, G Musto, ... Current Oncology 23 (4), 225-232, 2016 | 35 | 2016 |
| A comparative study of robust tests for spread: asymmetric trimming strategies HJ Keselman, RR Wilcox, J Algina, AR Othman, K Fradette British Journal of Mathematical and Statistical Psychology 61 (2), 235-253, 2008 | 32 | 2008 |
| Trends in time to diagnosis of colon cancer and impact on clinical outcomes H Singh, E Shu, A Demers, CN Bernstein, J Griffith, K Fradette Canadian Journal of Gastroenterology and Hepatology 26, 877-880, 2012 | 29 | 2012 |
| Phase 2 randomized cross-over trial of abiraterone+ prednisone (ABI+ P) vs enzalutamide (ENZ) for patients (pts) with metastatic castration resistant prostate cancer (mCPRC … D Khalaf, M Annala, DL Finch, CD Oja, J Vergidis, M Zulfiqar, ... Journal of Clinical Oncology 36 (15_suppl), 5015-5015, 2018 | 28 | 2018 |
| Factors associated with physical activity among Canadian high school students C Leggett, M Irwin, J Griffith, L Xue, K Fradette International Journal of Public Health 57, 315-324, 2012 | 24 | 2012 |
| Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov. 2018; 8 (4): 444–57 M Annala, G Vandekerkhove, D Khalaf, S Taavitsainen, K Beja, ... CD-17-0937.[Abstract][CrossRef][Google Scholar], 0 | 24 | |
| A population-based study of the use of radium 223 in metastatic castration-resistant prostate cancer: factors associated with treatment completion S Parimi, E Tsang, A Alexander, M McKenzie, F Bachand, K Sunderland, ... Canadian Urological Association Journal 11 (10), 350, 2017 | 22 | 2017 |
Kim N. ChiProfessor of Medicine, University of British ColumbiaVerified email at bccancer.bc.ca
